|
|
Artivion Inc (NYSE: AORT) |
|
Price: $29.6800
$0.34 
1.159%
|
| Day's High:
| $29.755
| Week Perf:
| 1.61 %
|
| Day's Low: |
$ 29.12 |
30 Day Perf: |
-0.5 % |
| Volume (M): |
199 |
52 Wk High: |
$ 30.45 |
| Volume (M$): |
$ 5,894 |
52 Wk Avg: |
$24.12 |
| Open: |
$29.42 |
52 Wk Low: |
$16.48 |
|
|
| Market Capitalization (Millions $) |
1,242 |
| Shares
Outstanding (Millions) |
42 |
| Employees |
1,250 |
| Revenues (TTM) (Millions $) |
383 |
| Net Income (TTM) (Millions $) |
-1 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
12 |
Artivion Inc
Artivion Inc is a technology company based in San Francisco, California, that focuses on providing solutions for the healthcare industry using emerging technologies such as artificial intelligence and machine learning. The company was founded in 2018 by a team of former Google employees and healthcare professionals.
Artivion's mission is to bring revolutionary advancements in healthcare by leveraging the power of data and artificial intelligence. The company is dedicated to creating innovative and cost-effective healthcare solutions that improve patient outcomes and drive efficiency in healthcare operations.
Artivion's flagship product is the Clinical Intent Engine (CIE), an AI-driven platform that helps healthcare professionals to quickly and accurately analyze medical records, identify clinical insights, and make informed decisions based on the available data. CIE is designed to integrate with existing electronic health records (EHR) systems and helps to identify patient risk factors, understand treatment options, and monitor outcomes.
In addition to the CIE platform, Artivion offers consulting services to healthcare organizations to help them optimize their workflows and improve their operations. The company also collaborates with leading academic institutions and healthcare organizations to develop cutting-edge solutions for the industry.
One of Artivion's key strengths is its team of experts in healthcare and artificial intelligence. The company's leadership includes experienced healthcare professionals, including physicians and clinical researchers, as well as experts in AI and machine learning. This combination of knowledge and expertise allows Artivion to develop solutions that are both clinically relevant and technologically advanced.
Overall, Artivion's focus on healthcare, advanced technology, and data-driven solutions positions the company well for growth and impact in the industry.
Company Address: 1655 Roberts Boulevard, NW Kennesaw 30144 GA
Company Phone Number: 419-3355 Stock Exchange / Ticker: NYSE AORT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Artivion Inc
As a Medical Equipment & Supplies company, Artivion Inc has been making significant strides in the market, evidenced by its recent financial results. With earnings per share turning positive and revenue experiencing substantial growth, the company is emerging as a promising player within the Medical Equipment & Supplies sector.
Artivion Inc's financial statements for the most recent fiscal period reveal an impressive earnings per share of $0.18, marking a significant improvement compared to the $-0.33 reported a year prior. Even in contrast to the preceding reporting season, when earnings per share stood at $-0.10, the company has managed to turn things around.
|
| Artivion Inc
Financial News Report: Artivion Inc Reports Improved EPS and Revenue Growth in the Fourth Quarter of 2023
Artivion Inc, a leading company in the Medical Equipment & Supplies industry, has released its financial report for the fourth quarter of 2023, covering the period from October to December 31. The company has shown significant improvement in its earnings per share (EPS) and revenue compared to the previous year.
In terms of EPS, Artivion Inc experienced a loss of $0.10 per share, which is an increase from a loss of $0.05 per share in the same period last year. However, it is worth noting that the company has shown improvement from the previous financial reporting period, with EPS improving from a loss of $0.24 per share.
|
| Artivion Inc
The stock market can be a rollercoaster ride, with ups and downs that can make even the most seasoned investor nervous. However, when we look deeper into the numbers and trends, we can find some silver linings that may bring a smile to investors' faces.
Artivion Inc, a medical equipment and supplies company, recently reported a 13.577% increase in revenue in the third quarter of 2023 compared to the same period last year. This is indeed a positive sign, showcasing the company's growth and ability to generate more income. Even though the company experienced a loss of $-0.24 per share, it's important to remember that revenue growth is a key factor in long-term success.
|
| Artivion Inc
Introduction
Artivion Inc, a prominent player in the market, exhibited favorable financial performance during the fiscal interval of April to June 2023. This article will delve into the various aspects of the company's performance, highlighting notable facts and figures from the period.
Improved Earnings Per Share (EPS)
Artivion Inc managed to diminish its loss per share, as they lowered it to $-0.08 per share compared to $-0.11 in the same period last year. Furthermore, the company's EPS also saw an improvement from $-0.33 per share in the previous reporting period.
|
| Artivion Inc
In the first financial quarter of 2023, Artivion Inc, a renowned corporation, has experienced mixed results. The company has reported a deficit per share of $-0.33 compared to $-0.08 in the last year, signifying an increase of $0.25 per share. Furthermore, the company experienced a decline in earnings per share, decreasing from $0.05 in the previous quarter.
However, Artivion Inc witnessed growth in its revenue, which advanced by 7.791 % to reach $83.23 million, as compared to $77.21 million during the same quarter of the previous year. The sequential revenue growth rose by 4.825 % to reach $79.40 million. These figures indicate that Artivion Inc was successful in increasing its revenue and expanding its customer base.
Despite the growth in revenue, the corporation realized a net deficit of $-13.532 million in the first financial quarter of 2023, which is higher than the deficit of $-3.389 million reported during the same period last year. These results indicate that the cost of operation might have increased compared to the revenue generated.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.02 $ |
| Revenues (TTM) |
9.15 $
|
| Cash Flow (TTM) |
0.06 $ |
| Cash |
1.34 $
|
| Book Value |
7.28 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.02 $
|
| Revenues (TTM) |
9.15 $ |
| Cash Flow (TTM) |
0.06 $ |
| Cash |
1.34 $
|
| Book Value |
7.28 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| North America |
|
 51.67 % |
of total Revenue |
| EMEA |
|
32.02 % |
of total Revenue |
| APAC |
|
10.91 % |
of total Revenue |
| LATAM |
|
6.21 % |
of total Revenue |
| Medical devices |
|
74.99 % |
of total Revenue |
| Preservation services |
|
25.82 % |
of total Revenue |
| Products |
|
74.99 % |
of total Revenue |
| Aortic stent grafts |
|
30.15 % |
of total Revenue |
| On-X |
|
22.61 % |
of total Revenue |
| Surgical sealants |
|
19.41 % |
of total Revenue |
| Other |
|
2.83 % |
of total Revenue |
|
|
3.48% 